SHARE

Novo Nordisk cuts sales forecasts

The Danish pharma group saw sales rise 18% but has cut sales and profits due to lower-than-expected US take-up of its GLP-1 obesity and diabetes drugs. However, operating profit for the Ozempic and Wegovy maker rose 20% in the quarter.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.